Coya Therapeutics (NASDAQ:COYA) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report published on Monday,Benzinga reports. D. Boral Capital currently has a $15.00 target price on the stock.

A number of other equities analysts have also issued reports on COYA. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, October 8th. Lake Street Capital reissued a “buy” rating and set a $17.00 price objective on shares of Coya Therapeutics in a research report on Wednesday, November 5th. HC Wainwright reaffirmed a “buy” rating on shares of Coya Therapeutics in a report on Monday, November 24th. BTIG Research raised their price target on Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, Wall Street Zen upgraded Coya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Coya Therapeutics Price Performance

NASDAQ COYA opened at $5.36 on Monday. The company has a fifty day moving average of $5.91 and a two-hundred day moving average of $6.06. The company has a market capitalization of $112.13 million, a PE ratio of -4.83 and a beta of 0.25. Coya Therapeutics has a 1 year low of $4.65 and a 1 year high of $8.29.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The firm had revenue of $3.56 million during the quarter, compared to analyst estimates of $3.70 million. Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%. On average, research analysts expect that Coya Therapeutics will post -1.15 earnings per share for the current year.

Hedge Funds Weigh In On Coya Therapeutics

A number of large investors have recently modified their holdings of COYA. Prosperity Wealth Management Inc. boosted its stake in shares of Coya Therapeutics by 16.4% in the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after buying an additional 3,350 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Coya Therapeutics during the 3rd quarter worth $28,000. Lantern Wealth Advisors LLC acquired a new position in shares of Coya Therapeutics during the 3rd quarter worth $66,000. Jane Street Group LLC grew its stake in shares of Coya Therapeutics by 101.7% during the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock worth $169,000 after purchasing an additional 13,176 shares during the period. Finally, Northwestern Mutual Wealth Management Co. purchased a new position in shares of Coya Therapeutics in the 2nd quarter valued at about $119,000. 39.75% of the stock is owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.